Stem Cell Scientists Awarded Nobel Prize in Physiology and Medicine

Kyodo / Reuters

Kyoto University Professor Shinya Yamanaka (left) and John Gurdon of the Gurdon Institute in Cambridge, England, at a symposium on induced pluripotent stem cells in Tokyo in April 2008

In a testament to the revolutionary potential of the field of regenerative medicine, in which scientists are able to create and replace any cells that are at fault in disease, the Nobel Prize committee on Monday awarded the 2012 Nobel in Physiology or Medicine to two researchers whose discoveries have made such cellular alchemy possible.

The prize went to John B. Gurdon of the University of Cambridge in England, who was among the first to clone an animal, a frog, in 1962, and to Shinya Yamanaka of Kyoto University in Japan who in 2006 discovered the four genes necessary to reprogram an adult cell back to an embryonic state.

Sir John Gurdon, who is now a professor at an institute that bears his name, earned the ridicule of many colleagues back in the 1960s when he set out on a series of experiments to show that the development of cells could be reversed. At the time, biologists knew that all cells in an embryo had the potential to become any cell in the body, but they believed that once a developmental path was set for each cell toward becoming part of the brain, or a nerve or muscle it could not be returned to its embryonic state. The thinking was that as a cell developed, it would either shed or silence the genes it no longer used, so that it would be impossible for a cell from an adult animal, for example, to return to its embryonic state and make other cells.

(MORE: Stem Cell Miracle? New Therapies May Cure Chronic Conditions Like Alzheimers)

Working with frogs, Gurdon proved his critics wrong, showing that some reprogramming could occur. Gurdon took the DNA from a mature frogs gut cell and inserted it into an egg cell. The resulting egg, when fertilized, developed into a normal tadpole, a strong indication that the genes of the gut cell were amenable to reprogramming; they had the ability to function as more than just an intestinal cell, and could give rise to any of the cells needed to create an entirely new frog.

Just as Gurdon was facing his critics in England, a young boy was born in Osaka, Japan, who would eventually take Gurdons finding to unthinkable extremes. Initially, Shinya Yamanaka would follow his fathers wishes and become an orthopedic surgeon, but he found himself ill-suited to the surgeons life. Intrigued more by the behind-the-scenes biological processes that make the body work, he found himself drawn to basic research, and began his career by trying to find a way to lower cholesterol production. That work also wasnt successful, but it drew him to the challenge of understanding what makes cells divide, proliferate and develop in specific ways.

In 2006, while at Kyoto University, Yamanaka stunned scientists by announcing he had successfully achieved what Gurdon had with the frog cells, but without using eggs at all. Yamanaka mixed four genes in with skin cells from adult mice and turned those cells back to an embryo-like state, essentially erasing their development and turning back their clock. The four genes reactivated other genes that are prolific in the early embryo, and turned off those that directed the cells to behave like skin.

(MORE: Ovary Stem Cells Can Produce New Human Eggs)

See the original post here:

Stem Cell Scientists Awarded Nobel Prize in Physiology and Medicine

Foundation Medicine to Collaborate with Eisai on International Oncology Clinical Trial

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Foundation Medicine, Inc. announced today a multi-year collaboration with Eisai Co., Ltd., Tokyo, Japan for genomic profiling and diagnostic discovery in a multi-site, international clinical trial of an Eisai targeted therapeutic candidate. The goal of the collaboration is to prospectively identify specific genomic alterations in each patients tumor and use the results to inform patient stratification, to guide drug development decisions and potentially for the commercialization of new molecular diagnostics. Foundation Medicine will receive an upfront payment and is eligible for future diagnostic rights.

Eisai is dedicated to bringing new treatment options to cancer patients, said Takashi Owa, Ph.D., chief innovation officer, Eisai. This collaboration with Foundation Medicine, utilizing their depth of molecular oncology knowledge and ability to partner on a global scale, will help Eisai better understand the genomic makeup of each patient as we work to deliver new targeted treatments that may benefit patients.

This collaboration represents the continued advancement of our partnership strategy as we gain greater understanding into the key alterations driving tumor growth, said Michael J. Pellini, M.D., president and chief executive officer, Foundation Medicine. By using our comprehensive genomic profile to inform trial enrollment and outcomes analysis, Eisai can reveal the genomic drivers of an individual patients disease and may be able to more rapidly advance effective targeted treatments for cancer.

About Foundation Medicine

Foundation Medicine is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patients unique cancer. The companys initial clinical product, FoundationOne, is a fully informative genomic profile to identify a patients individual molecular alterations and match them with relevant targeted therapies and clinical trials. Foundation Medicines molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit http://www.foundationmedicine.com.

About Eisai Co., Ltd.

Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai, please visit http://www.eisai.com.

More:

Foundation Medicine to Collaborate with Eisai on International Oncology Clinical Trial

Britain's Gurdon, Japan's Yamanaka share Nobel medicine prize for stem cell research

NEW YORK, N.Y. - Two scientists from different generations won the Nobel Prize in medicine Monday for the groundbreaking discovery that cells in the body can be reprogrammed into completely different kinds, work that reflects the mechanism behind cloning and offers an alternative to using embryonic stem cells.

The work of British researcher John Gurdon and Japanese scientist Shinya Yamanaka who was born the year Gurdon made his discovery holds hope for treating diseases like Parkinson's and diabetes by growing customized tissue for transplant.

And it has spurred a new generation of laboratory studies into other illnesses, including schizophrenia, which may lead to new treatments.

Basically, Gurdon, 79, and Yamanaka, 50, showed how to make the equivalent of embryonic stem cells without the ethical questions those very versatile cells pose, a promise scientists are now scrambling to fulfil.

Once created, these "blank slate" cells can be nudged toward developing into other cell types. Skin cells can ultimately be transformed into brain cells, for example.

Just last week, scientists reported turning skin cells from mice into eggs that produced baby mice, a possible step toward new fertility treatments.

Gurdon and Yamanaka performed "courageous experiments" that challenged scientific opinion, said Doug Melton, co-director of the Harvard Stem Cell Institute.

"Their work shows ... that while cells might be specialized to do one thing, they have the potential to do something else," Melton said. It "really lays the groundwork for all the excitement about stem cell biology."

Another Harvard stem cell researcher, Dr. George Daley said, "I don't think anybody is surprised" by the award announcement. "The fact that these two share it together is inspired."

In announcing the $1.2 million award, the Nobel committee at Stockholm's Karolinska Institute said the work has "revolutionized our understanding of how cells and organisms develop."

Read the rest here:

Britain's Gurdon, Japan's Yamanaka share Nobel medicine prize for stem cell research

Reproductive Medicine Associates of New York Opens New Fertility Center in Downtown Brooklyn

NEW YORK, Oct. 8, 2012 /PRNewswire/ -- Reproductive Medicine Associates of New York (RMA of New York), a world class fertility program well known for its compassionate care and clinical excellence, proudly announces the opening of a new reproductive medicine facility in Downtown Brooklyn. Located directly opposite Brooklyn Borough Hall, RMA of New YorkBrooklyn sits on the 27th floor of 26 Court Street, easily accessible by nine subway lines and in close proximity to Brooklyn neighborhoods. Dr. Joshua U. Klein, reproductive endocrinologist, fertility specialist and Brooklyn native, will serve as Medical Director of the new facility.

The founders of RMA of New York recognized a clear need for high quality fertility services in Brooklyn given the borough's significant growth and the cultural, religious and economic diversity of its population. "There is no doubt that Brooklyn is experiencing a true renaissance. By opening RMA of New YorkBrooklyn and providing the area with cutting-edge fertility care, scientific and medical excellence, and access to a top IVF laboratory, we will contribute to this dynamic growth," says Dr. Alan Copperman, Co-Medical Director of RMA of New York. "Since 2001, we have cared for thousands of Brooklyn-based patients in our Manhattan office. RMA of New YorkBrooklyn will provide the highest quality fertility care in a convenient, comfortable, and personalized setting, and will help our patients achieve their dreams of creating a family."

A graduate of Harvard Medical School, Dr. Joshua Klein completed his residency training in obstetrics and gynecology at Brigham and Women's Hospital and Massachusetts General Hospital, and fellowship training in reproductive endocrinology and infertility at Columbia University Medical Center. Dr. Klein plans a medical affiliation with Long Island College Hospital/University Hospital Brooklyn (Downstate) and carries an academic appointment at Mount Sinai School of Medicine in Manhattan as an Assistant Professor of Clinical OB/GYN.

"This is an exciting time in reproductive medicine. For the first time, we are beginning to offer next generation fertility care to the first generation of children born from IVF and we are rapidly improving upon all current fertility treatments," Dr. Klein stated enthusiastically. "I am excited to join RMA of New York because of its strong track record of success and focus on blending the most advanced medical science with a dedication to individualized patient care. Having grown up here, I look forward to providing fertility care at the highest possible level to patients spanning the full ethnic, religious, and cultural mosaic that makes Brooklyn such a special and wonderful place to live and work."

Reproductive Medicine Associates of New York (RMA of New York) is widely recognized as a national and international leader in state-of-the-art reproductive medicine. Led by an integrated team of doctors and scientists with extensive reproductive endocrinology, fertility and urology experience and training, RMA of New York consistently reports success rates to the Society for Assisted Reproductive Technology (SART) and the Center for Disease Control and Prevention (CDC) that are among the highest in the country and the world. RMA of New York maximizes access to care by helping patients explore all insurance coverage and financing options available for treatment. Headquartered in midtown Manhattan, RMA of New York has additional facilities in Garden City, White Plains and Brooklyn. For more information, please visit http://www.rmany.com.

Originally posted here:

Reproductive Medicine Associates of New York Opens New Fertility Center in Downtown Brooklyn

Medicine prize kicks off Nobel prizes

THE 2012 Nobel Prize season opens with the pick for the medicine award, marking the start of a week of announcements and speculation over who will collect the literature and peace prizes.

The medicine prize will be announced in Stockholm at 11:30am (2030 AEDT) at the earliest.

With the awards committees keeping mum on their choices, Nobel watchers are left to play a guessing game.

Swedish media have suggested the medicine prize could go to Japan's Shinya Yamanaka and Britain's John Gurdon for their research in nuclear reprogramming, a process that instructs adult cells to form early stem cells which can then be used to form any tissue type.

James Till of Canada could also be honoured for his related work on blood stem cells.

Other medicine fields cited as worthy of Nobel recognition this year are epigenetics, which studies how genes respond to their environment, and optogenetics, where researchers can turn on or off a nerve cell, for example in a fruit fly or a mouse, to reprogram the brain.

The winner of the Nobel Peace Prize, perhaps the most watched of the prestigious awards, will be revealed Friday in Oslo, and the five-member Norwegian Nobel committee has 231 nominees to choose from this year.

No clear frontrunner has emerged so far, though Coptic Christian Maggie Gobran of Egypt, dubbed the "Mother Teresa" of Cairo's slums, tops the list of one betting site with odds of 6.5-to-1.

The committee keeps the list of nominees a well-guarded secret, but those who are entitled to nominate candidates can disclose the names they have put forward so the list is known to include former US president Bill Clinton, ex-German chancellor Helmut Kohl, the EU and WikiLeaks suspect Bradley Manning.

The head of the Peace Research Institute of Oslo, Kristian Berg Harpviken, follows the work of the committee and each year publishes his own shortlist of possible winners.

Read more:

Medicine prize kicks off Nobel prizes

Nobel Prize for medicine awarded to Gurdon, Yamanaka for stem cell discoveries

British scientist John Gurdon and Japanese researcher Shinya Yamanaka shared the 2012 Nobel Prize in physiology or medicine Monday for experiments separated by almost 50 years that provide deep insight into how animals develop and offer hope for a new era of personalized medicine.

Their findings have revolutionized our understanding of how cells and organisms develop, the Nobel committee said in the prize announcement.

In 1962, Gurdon wowed the world of biology by cloning a frog via a clever technique. He transplanted the genetic material from an intestinal cell of one frog into the fertilized egg cell from another. The egg developed into a tadpole, proving that all of the genetic instructions needed to turn an embryo into an adult exist even in so-called adult cells of the body the specialized cells that make up skin, muscle, nerves and other tissues.

In 2006 and 2007, Yamanaka extended that insight by turning back time on individual cells from both mice and humans. By sprinkling four genes on ordinary skin cells, Yamanaka discovered a virtual fountain of youth for cells: Any type of cell, he found, could be reverted to a young, embryonic state. These induced embryonic cells behave much like the ethically contentious stem cells gleaned from human embryos. They can be grown into many other types of tissues but without having to destroy any embryos.

The breakthrough offered hope that someday, skin cells could be harvested from a patient, sent back in time to an embryonic state, and then grown into replacement tissues such as heart muscle or nerve cells.

Yamanakas breakthrough has spawned a huge research global effort to turn these induced pluripotent stem cells, as theyre called, into therapies tailored to individual patients for a wide range of ailments, including heart disease, some forms of blindness, Parkinsons disease and many other disorders.

The first human trials of such therapies could begin next year, Yamanaka told the journal Nature earlier this year. He said eye diseases present an attractive target for the first tests.

On Monday, Yamanaka credited his co-laureate for making his advances possible. This field has a long history starting with John Gurdon, he said in a brief telephone interview posted on the Nobel Prize Web site. Yamanaka noted he was born in 1962 the year Gurdon published his pivotal frog experiments.

A surgeon by training, Yamanaka, who splits his time between Japans Kyoto University and the University of California, San Francisco, said treating patients has always been his aim. My goal all my life is to bring this stem cell technology to the bedside, to patients.

But the therapeutic potential of induced stem cells remains in question. Some experiments show the cells may form tumors, prompting skepticism that they will ever be safe enough to treat heart disease, Parkinsons disease and many other conditions where specific cells of the body break down.

Read more from the original source:

Nobel Prize for medicine awarded to Gurdon, Yamanaka for stem cell discoveries

British, Japanese scientists win Nobel medicine prize

STOCKHOLM British researcher John Gurdon and Shinya Yamanaka of Japan won this year's Nobel Prize in physiology or medicine on Monday for discovering that mature, specialized cells of the body can be reprogrammed into stem cells -- a discovery that scientists hope to turn into new treatments.

Scientists want to harness that reprogramming to create replacement tissues for treating diseases like Parkinson's, diabetes and for studying the roots of diseases in the laboratory.

The prize committee at Stockholm's Karolinska Institute said the discovery has "revolutionized our understanding of how cells and organisms develop."

Gurdon showed in 1962 -- the year Yamanaka was born -- that the DNA from specialized cells of frogs, like skin or intestinal cells, could be used to generate new tadpoles. That showed the DNA still had its ability to drive the formation of all cells of the body.

In 1997, the cloning of Dolly the sheep by other scientists showed that the same process Gurdon discovered in frogs would work in mammals.

More than 40 years after Gurdon's discovery, in 2006, Yamanaka showed that a surprisingly simple recipe could turn mature cells back into primitive cells, which in turn could be prodded into different kinds of mature cells.

- The Nobel committee

Basically, the primitive cells were the equivalent of embryonic stem cells, which had been embroiled in controversy because to get human embryonic cells, human embryos had to be destroyed. Yamanaka's method provided a way to get such primitive cells without destroying embryos.

"The discoveries of Gurdon and Yamanaka have shown that specialized cells can turn back the developmental clock under certain circumstances," the committee said. "These discoveries have also provided new tools for scientists around the world and led to remarkable progress in many areas of medicine."

Just last week, Japanese scientists reported using Yamanaka's approach to turn skin cells from mice into eggs that produced baby mice.

Continued here:

British, Japanese scientists win Nobel medicine prize

Factbox: A look at the Nobel Medicine Prize

(Reuters) - Here is a look at the 2012 Nobel Prize for Physiology or Medicine, which was awarded jointly on Monday to John B. Gurdon and Shinya Yamanaka.

* The 2012 prize was awarded "for the discovery that mature cells can be reprogrammed to become pluripotent". The two scientists discovered that mature, specialized cells can be reprogrammed to become immature cells capable of developing into all tissues of the body. Their findings revolutionized understanding of how cells and organisms develop.

* Nobel Prizes in Physiology or Medicine have been awarded 102 times since 1901. In all but 38 cases they were given to more than one recipient.

* Of the 199 individuals awarded the Nobel Prize in Physiology or Medicine, only ten are women. Of these eight, Barabara McClintock is the only one who has received an unshared Nobel Prize.

* Famous Winners: Robert Koch, the German physician and bacteriologist, won in 1905 for his work on tuberculosis. Frederick Banting, the Canadian physiologist who with his assistant Charles Best discovered insulin, the principal remedy for diabetes, won the prize in 1923.

* The oldest living recipient is Rita Levi-Montalcini, the first Nobel laureate to reach her hundredth birthday, who won the prize in 1986 with Stanley Cohen for their discoveries of growth factors. She celebrated her 103rd birthday last April.

Sources: Reuters, http://nobelprize.org. Chambers Biographical Dictionary.

(Reporting by David Cutler, London Editorial Reference Unit)

The rest is here:

Factbox: A look at the Nobel Medicine Prize

Medicine prize kicks off Nobel week

The 2012 Nobel Prize season opens Monday with the award for medicine, marking the start of a week of announcements and speculation over who will collect the literature and peace prizes.

The medicine prize will be announced in Stockholm at 11:30 am (0930 GMT) at the earliest.

With the awards committees keeping mum on their choices, Nobel watchers are left to play a guessing game.

Swedish media have suggested the medicine prize could go to Japan's Shinya Yamanaka and Britain's John Gurdon for their research in nuclear reprogramming, a process that instructs adult cells to form early stem cells which can then be used to form any tissue type.

James Till of Canada could also be honoured for his related work on blood stem cells.

Other medicine fields cited as worthy of Nobel recognition this year are epigenetics, which studies how genes respond to their environment, and optogenetics, where researchers can turn on or off a nerve cell, for example in a fruit fly or a mouse, to reprogramme the brain.

Japanese media voiced hope Yamanaka was in with a chance, with the Nikkei business daily declaring he was a "sure" thing for a Nobel one day, but conceding it might not be this year.

"It's a matter of time," it said.

The winner of the Nobel Peace Prize, perhaps the most watched of the prestigious awards, will be revealed Friday in Oslo, and the five-member Norwegian Nobel committee has 231 nominees to choose from this year.

No clear frontrunner has emerged so far, although Coptic Christian Maggie Gobran of Egypt, dubbed the "Mother Teresa" of Cairo's slums, tops the list of one betting site with odds of 6.5-to-1.

Read the rest here:

Medicine prize kicks off Nobel week

Recent winners of the Nobel Prize in medicine

Recent winners of the Nobel Prize in physiology or medicine, and their research, according to the Nobel Foundation:

2012: Briton John Gurdon and Japan's Shinya Yamanaka for their discovery that mature cells can be reprogrammed into immature cells that can be turned into all tissues of the body, a finding that revolutionized understanding of how cells and organisms develop.

2011: American Bruce Beutler and French researcher Jules Hoffmann for their discoveries concerning the activation of innate immunity, sharing it with Canadian-born Ralph Steinman for his discovery of the dendritic cell and its role in adaptive immunity.

2010: British researcher Robert Edwards for the development of in vitro fertilization.

2009: Americans Elizabeth Blackburn, Carol Greider and Jack Szostak for their discovery of how chromosomes are protected by telomeres and the enzyme telomerase, research that has implications for cancer and aging research.

2008: Harald zur Hausen and Francoise Barre-Sinoussi and Luc Montagnier for discoveries of human papilloma viruses causing cervical cancer and the discovery of human immunodeficiency virus.

2007: Mario R. Capecchi and Oliver Smithies of the United States and Martin J. Evans of the United Kingdom, for their discoveries leading to a powerful technique for manipulating mouse genes.

2006: Andrew Z. Fire and Craig C. Mello, of the United States, for their work in controlling the flow of genetic information.

2005: Barry J. Marshall and Robin Warren, of Australia, for their work in how the bacterium Helicobacter pylori plays a role in gastritis and peptic ulcer disease.

2004: Richard Axel and Linda B. Buck, both of the United States, for their work in studying odorant receptors and the organization of the olfactory system in human beings.

The rest is here:

Recent winners of the Nobel Prize in medicine

Nobel Prize for Medicine Awarded

A British researcher and a Japanese scientist won the Nobel Prize in physiology or medicine on Monday for discovering that ordinary cells of the body can be reprogrammed into stem cells, which then can turn into any kind of tissue a discovery that may led to new treatments.

Scientists want to build on the work by John Gurdon and Shinya Yamanaka to create replacement tissues for treating diseases like Parkinson's and diabetes, and for studying the roots of diseases in the laboratory without the ethical dilemma posed by embryonic stem cells.

In announcing the 8 million kronor ($1.2 million) award, the Nobel committee at Stockholm's Karolinska Institute said the discovery has "revolutionized our understanding of how cells and organisms develop."

Gurdon showed in 1962 the year Yamanaka was born that the DNA from specialized cells of frogs, like skin or intestinal cells, could be used to generate new tadpoles. That showed the DNA still had its ability to drive the formation of all cells of the body.

At the time, the discovery had "no obvious therapeutic benefit at all," Gurdon told reporters in London.

"It was almost 50 years before the value the potential value of that basic scientific research comes to light," he said.

In 1997, the cloning of Dolly the sheep by other scientists showed that the same process Gurdon discovered in frogs would work in mammals.

AP

More than 40 years after Gurdon's discovery, in 2006, Yamanaka showed that a surprisingly simple recipe could turn mature cells back into primitive cells, which in turn could be prodded into different kinds of mature cells.

Basically, the primitive cells were the equivalent of embryonic stem cells, which had been embroiled in controversy because to get human embryonic cells, human embryos had to be destroyed. Yamanaka's method provided a way to get such primitive cells without destroying embryos.

See the rest here:

Nobel Prize for Medicine Awarded

Gurdon, Yamanaka win Nobel medicine prize

STOCKHOLM (AP) British researcher John Gurdon and Shinya Yamanaka of Japan won this year's Nobel Prize in medicine on Monday for discovering that mature, specialized cells of the body can be reprogrammed into stem cells a discovery that scientists hope to turn into new treatments.

Scientists want to harness that reprogramming to create replacement tissues for treating diseases like Parkinson's and for studying the roots of diseases in the laboratory.

The prize committee at Stockholm's Karolinska Institute said the discovery has "revolutionized our understanding of how cells and organisms develop."

Gurdon showed in 1962 that the DNA from specialized cells of frogs, like skin or intestinal cells, could be used to generate new tadpoles. That showed the DNA still had its ability to drive the formation of all cells of the body.

More than 40 years later, in 2006, Yamanaka showed that a surprisingly simple recipe could turn mature cells back into primitive cells, which in turn could be prodded into different kinds of mature cells.

Basically, the primitive cells were the equivalent of embryonic stem cells, which had been embroiled in controversy because to get human embryonic cells, human embryos had to be destroyed. Yamanaka's method provided a way to get such primitive cells without destroying embryos.

"The discoveries of Gurdon and Yamanaka have shown that specialized cells can turn back the developmental clock under certain circumstances," the committee said. "These discoveries have also provided new tools for scientists around the world and led to remarkable progress in many areas of medicine."

Just last week, Japanese scientists reported using Yamanaka's approach to turn skin cells from mice into eggs that produced baby mice.

Gurdon, 79, has served as a professor of cell biology at Cambridge University's Magdalene College and is currently at the Gurdon Institute in Cambridge, which he founded. Yamanaka, born in 1962, worked at the Gladstone Institute in San Francisco and Nara Institute of Science and Technology in Japan.

Goran Hansson, the secretary of the prize committee, said he had reached both winners before the announcement.

Visit link:

Gurdon, Yamanaka win Nobel medicine prize

Nobel Prize in medicine awarded for reprogrammed cells

The Nobel Prize for medicine is the first in a series of prizes being announced this week.

STORY HIGHLIGHTS

Read a version of this story in Arabic

(CNN) -- The 2012 Nobel Prize for Physiology or Medicine was awarded Monday to Sir John B. Gurdon and Shinya Yamanaka for work that revolutionized the understanding of how cells and organisms develop.

The Nobel Assembly's announcement at the Karolinska Institute in Stockholm is the first for what will be a series of prizes announced this week. The Norwegian Nobel committee will announce the most anticipated of the annual honors -- the Nobel Peace Prize -- on Friday in Oslo.

Gurdon, 79, of Dippenhall, England, and Yamanaka, 50, of Osaka, Japan, share the prize jointly "for the discovery that mature cells can be reprogrammed to become pluripotent" -- the ability of a cell to differentiate into another cell type, according to the Nobel committee.

Shinya Yamanaka (pictured) and Sir John B. Gurdon won the Nobel Prize in medicine for their revolutionary cell research.

Gurdon discovered in 1962 that the cells are reversible in an experiment with an egg cell of a frog. Yamanaka discovered 40 years later that mature cells in mice could be reprogrammed as immature cells, the committee said.

"These groundbreaking discoveries have completely changed our view of the development and cellular specialisation. We now understand that the mature cell does not have to be confined forever to its specialised state," the Nobel Assembly said in a statement following the announcement.

"Textbooks have been rewritten and new research fields have been established. By reprogramming human cells, scientists have created new opportunities to study diseases and develop methods for diagnosis and therapy.

Read more here:

Nobel Prize in medicine awarded for reprogrammed cells

Nobel Prize in medicine awarded to Sir John Gurdon, Shinya Yamanaka

The Nobel Prize for medicine is the first in a series of prizes being announced this week.

STORY HIGHLIGHTS

Read a version of this story in Arabic

(CNN) -- The 2012 Nobel Prize for Physiology or Medicine was awarded Monday to Sir John B. Gurdon and Shinya Yamanaka for work that revolutionized the understanding of how cells and organisms develop.

The Nobel Assembly's announcement at the Karolinska Institute in Stockholm is the first for what will be a series of prizes announced this week. The Norwegian Nobel committee will announce the most anticipated of the annual honors -- the Nobel Peace Prize -- on Friday in Oslo.

Gurdon, 79, of Dippenhall, England, and Yamanaka, 50, of Osaka, Japan, share the prize jointly "for the discovery that mature cells can be reprogrammed to become pluripotent" -- the ability of a cell to differentiate into another cell type, according to the Nobel committee.

Shinya Yamanaka (pictured) and Sir John B. Gurdon won the Nobel Prize in medicine for their revolutionary cell research.

Gurdon discovered in 1962 that the cells are reversible in an experiment with an egg cell of a frog. Yamanaka discovered 40 years later that mature cells in mice could be reprogrammed as immature cells, the committee said.

"These groundbreaking discoveries have completely changed our view of the development and cellular specialisation. We now understand that the mature cell does not have to be confined forever to its specialised state," the Nobel Assembly said in a statement following the announcement.

"Textbooks have been rewritten and new research fields have been established. By reprogramming human cells, scientists have created new opportunities to study diseases and develop methods for diagnosis and therapy.

See original here:

Nobel Prize in medicine awarded to Sir John Gurdon, Shinya Yamanaka

Tone Up: Medicine ball workout

Medicine balls provide a great workout for those looking for something a little different from machines or even free weights. In the video below, Marcie Fraser shows how to use medicine balls to work the upper body, while also getting the lower body involved.

To view our videos, you need to enable JavaScript. Learn how. install Adobe Flash 9 or above. Install now. Then come back here and refresh the page.

Read the original:

Tone Up: Medicine ball workout

Rajasthan's free medicine scheme benefits 200,000 people daily

Jaipur, Oct 7 (IANS) The free medicine scheme launched by Chief Minister Ashok Gehlot a year ago on Mahatma Gandhi's birth anniversary Oct 2 has seen a footfall of 70 million people at the distribution centres, officials said Sunday.

"Two lakh (200,000) people take advantage of this scheme every day. Some patients have benefitted more than once. They are being given free essential medicines at 15,355 medicine distribution centres and in all the government hospitals," a senior official said.

Rajasthan has a population of 68.6 million people, and is the first to run the free medicine scheme on such a large scale, the official claimed.

"In the second year of the scheme, the state government has allocated Rs.300 crore. The chief minister has also directed that the number of distribution centres and the medicines being given under the scheme also be increased."

Nearly 400 types of generic drugs and surgical items are available for free distribution under the existing scheme. These drugs are provided free of charge to patients at primary healthcare centres, community healthcare centres, district hospitals and medical colleges, officials said.

Apart from the free medicine, the government is also planning to make free diagnostic tests at the hospitals run by it.

Chief Minister Gehlot has already assured that there would not be any problem in financing any health-related scheme. "If the people are given free medicines and good care, their trust in government hospitals will increase," the chief minister said recently.

Addressing a workshop recently, he also said that the results of the scheme were very encouraging and the central government was planning to implement the scheme across the country based on the success of the Rajasthan model.

The number of patients visiting government-run hospitals has gone by up by almost 50 percent in the last one year, largely due to the free medicine scheme. The chief minister also recently launched a helpline to prove information about the scheme.

"Every member of the society is eligible. The poor are given priority. Persons below the poverty line and weaker sections can shed their worries over healthcare expenses," a health department official said.

See the article here:

Rajasthan's free medicine scheme benefits 200,000 people daily

Medicine Drop

Published: Saturday, October 6, 2012 at 20:00 PM.

The Neuse Riverkeeper Foundation expresses great appreciation to the residents of New Bern and Craven County who took the time and interest to bring 250 pounds of drugs to the Operation Medicine Drop held at Realo Drugs on Saturday. The presence of a police officer is required and we were blessed once again to have the help of Officer Shelton Brown. Volunteers gave generously of their time to make the river and local homes cleaner and safer. We are told by NCSAFE KIDSthat this amount of poundage translates into 125,000 doses of drugs. We hope to soon be able to install a drop box in the City of New Bern Police Department where drugs may be safely deposited no questions asked. We thank Chief Toussaint Summers for his genuine concern for our community and the support his officers give our youth. If you missed this dropoff be looking for another this spring. Natalie Baggett, New Bern

The Neuse Riverkeeper Foundation expresses great appreciation to the residents of New Bern and Craven County who took the time and interest to bring 250 pounds of drugs to the Operation Medicine Drop held at Realo Drugs on Saturday. The presence of a police officer is required and we were blessed once again to have the help of Officer Shelton Brown. Volunteers gave generously of their time to make the river and local homes cleaner and safer. We are told by NCSAFE KIDSthat this amount of poundage translates into 125,000 doses of drugs. We hope to soon be able to install a drop box in the City of New Bern Police Department where drugs may be safely deposited no questions asked. We thank Chief Toussaint Summers for his genuine concern for our community and the support his officers give our youth. If you missed this dropoff be looking for another this spring. Natalie Baggett, New Bern

See the original post here:

Medicine Drop

Free TeamHealth iPad Application Offers Custom, Streamlined Job Search Tool for Emergency Medicine Providers

KNOXVILLE, Tenn., Oct. 5, 2012 /PRNewswire/ --Today, TeamHealth announced the launch of its new iPad application, TeamHealth Careers, a customizable job search tool that allows users to access hundreds of emergency medicine positions across the country. Through the TeamHealth Careers app, users have the unique ability to filter their career search by community, region or nationwide while also searching for positions that meet clinical preferences such as annual volume. TeamHealth Careers also provides information about schools, restaurants and activities in the community of the user's choice and allows users to apply for positions and contact TeamHealth recruiters.

"At TeamHealth, we know that choosing an emergency medicine career is about much more than simply filling a position," said Susan Masterson, Vice President of Provider Recruitment. "The TeamHealth Careers app puts the power at the user's fingertips, allowing providers to conveniently customize and streamline their job search process."

For more information about TeamHealth Careers, visit MyEMCareer.com. Download TeamHealth Careers in the iPad app store.

About TeamHealth TeamHealth (Knoxville, Tenn.) (TMH) is one of the largest providers of outsourced physician staffing solutions for hospitals in the United States. Through its 17 regional locations and multiple service lines, TeamHealth's more than 8,300 affiliated healthcare professionals provide emergency medicine, hospital medicine, anesthesia, urgent care, and pediatric staffing and management services to approximately 790 civilian and military hospitals, clinics, and physician groups in 47 states. The term "TeamHealth" as used throughout this release includes Team Health, Inc., and all of its related entities, divisions, subsidiaries and affiliated physicians and physician groups. For more information about TeamHealth, visit http://www.teamhealth.com.

Read the original:

Free TeamHealth iPad Application Offers Custom, Streamlined Job Search Tool for Emergency Medicine Providers

Dallas federal prosecutors join Medicine Abuse Project campaign to curb abuse of legal drugs

New, 2:29 p.m.

The U.S. Attorneys Office in Dallas says it has joined a nationwide effort to stop the abuse of prescription medication.

The campaign from Partnership at Drugfree.org is called the Medicine Abuse Project.

The Northern District of Texas will hold several events as part of the campaign. The primary focus will be to help save lives by warning the public, and teenagers in particular, about the dangers of abusing prescription and over-the-counter medicines.

Prescription drug abuse is an epidemic, especially among our teens, said U.S. Attorney Sarah R. Saldaa.

Also taking part will be the Council on Alcohol & Drug Abuse, the Dallas Area Drug Prevention Partnership, local police departments, and federal agencies such as the Drug Enforcement Administration.

Saldaa said last weekends prescription drug Take-Back initiative was a big success and set records locally for the disposal of expired and unwanted medications.

DEA Special Agent in Charge James L. Capra, of the Dallas division, said the agency collected 14,468 pounds of drugs from 70 collection sites in the region.

Prescription drug abuse has become a serious public health and safety issue and it is the nations fastest-growing drug problem, Capra said.

The U.S. Attorneys Office said 2,500 teens use a prescription drug every day to get high for the first time. The number of deaths from prescription painkillers has tripled over the past decade.

The rest is here:

Dallas federal prosecutors join Medicine Abuse Project campaign to curb abuse of legal drugs

Transfusion Medicine RFID Consortium details plans for commercializing technology to track and monitor blood products …

PORTLAND, Ore., Oct. 5, 2012 /PRNewswire/ --The Transfusion Medicine RFID Consortium announced today that S3Edge Inc., the software partner for the consortium has been selected to exclusively commercialize the RFID and barcode based Blood Product Tracking suite of applications designed and built under a private, academic, and public initiative funded by the NIH. The system, consisting of mobile, desktop, and server software applications provides greater visibility to the physical movement of blood products, while improving the efficiency of Blood Center operations. The RFID consortium includes BloodCenter of Wisconsin, SysLogic Inc., S3Edge Inc., Carter Bloodcare, Mississippi Blood Services, the University of Iowa Hospitals and Clinics, Mississippi Baptist Health System, University of Wisconsin Madison RFID Laboratory, and Mediware Corp.

The suite of applications has been deployed in a production pilot at the BloodCenter of Wisconsin and the University of Iowa Hospitals and Clinics (UIHC) with promising results. "Thanks to the outstanding work of the entire consortium team, we have successfully piloted the new system to track blood products as they move from fixed and mobile donation sites, through the blood center and to distribution. After 24 weeks of running the system in a pilot mode here at the BloodCenter of Wisconsin, we have seen process efficiency and traceability gains, as well as marked improvements in reconciliation," said Lynne Briggs, Vice President and Chief Information Officer for BloodCenter of Wisconsin in Milwaukee.

The hospital transfusion services tracking module was piloted at the DeGowin Blood Center at UIHC where it was run in parallel with IPR, an internally developed barcode-based tracking system. "The RFID system provided equivalent capabilities to those of IPR in terms of detecting and resolving process errors. It additionally provided the blood bank staff real-time visibility for blood products in transit from the hospital blood bank to the point-of-care and in remote storage in our emergency department." said Dr. Thomas J. Raife, MD, Clinical Professor & Medical Director, UIHC DeGowin Blood Center.

The initiative to introduce RFID technology in transfusion medicine is also a showcase of how ground-breaking solutions can be very effectively designed, developed, and commercialized via private-academic-public initiatives for the healthcare industry. "This effort represents the culmination of years of hard work by the consortium members in bringing a much needed innovation to the market in a collaborative manner. We are pleased to see S3Edge taking the next steps to ensure that the cumulative efforts of the consortium benefit the transfusion medicine industry as a whole," said Rodeina Davis who was the principal investigator for the STTR grant, and a luminary in the transfusion medicine field recognized for her role in advancing this new technology from idea to adoption.

SysLogic Inc., one of the founding members of the consortium and awardee of the STTR grant allowing for creation of the system will continue to spearhead efforts to obtain the 510(k) clearance for the blood product tracking suite of applications developed by the consortium. "Today's announcement solidifies our commitment not just to create compelling technology, but to realize the vision of creating a successful product for the transfusion medicine industry. We look forward to completing the requirements for the 510(k) clearance and facilitate the technology's potential to transform current operations in the transfusion medicine industry for all end-users," said Tina Chang, CEO of SysLogic Inc., a Brookfield, Wisconsin-based information systems consulting and services firm.

"S3Edge is extremely pleased to lead the commercialization effort and make the technology broadly available to the transfusion medicine industry. This significant milestone could not have happened without the efforts, guidance and leadership of the consortium. We look forward to working in tandem with this team of health care stakeholders and distinguished researchers to ensure Blood Centers around the world can take full advantage of this new system," said Mark Anastas, President of S3Edge Inc.

To learn more about the RFID blood product tracking initiative and the commercialization plans, visit the S3Edge booth (#579) at the AABB Annual Meeting & CTTXPO 2012 to be held in Boston from October 6-9th, 2012.

About S3Edge Inc.

S3Edge Inc., a member of the TM RFID Consortium (http://www.transfusionmedicinerfid.org) is a software product company that provides packaged, Auto-ID-based tracking solutions for automation and error proofing of healthcare supply chain operations. Spotlight, S3Edge's software product enables enterprises to configure and view assets, zones, alerts, and reports and to track and obtain trends on asset movement within their organizations. For more information, visit http://www.s3edge.com.

Press-Release Contact: Anush Kumar, S3Edge Inc., E-mail: anush@s3edge.com, Phone: 424-832-113.

Continue reading here:

Transfusion Medicine RFID Consortium details plans for commercializing technology to track and monitor blood products ...